SHINE-2 and Closing the Pediatric UC Treatment Gap, With Marla Dubinsky, MD
Eli Lilly's mirikizumab showed positive results in treating pediatric ulcerative colitis in the phase 3 SHINE-2 study, with 41.3% of participants achieving clinical remission at week 12. The drug is not yet approved for pediatric use, but Lilly plans to submit the data to global regulators. Current treatments for pediatric UC are limited, and mirikizumab could address this gap.
How this was made
The 30-second read
Why it matters
The data suggest a high clinical remission rate (41.3% at week 12) and strong endoscopic outcomes, positioning Lilly for a potential label expansion.
Market read
First positive pediatric UC data from a major biotech could drive stock movement and influence the broader gastro‑enterology therapeutic landscape.
What to watch
Pediatric dosing complexities and reimbursement uncertainties may limit commercial upside.
Background
Pediatric ulcerative colitis currently has only three approved biologics; mirikizumab could become the first IL‑23p19 inhibitor for this age group.
Ticker impact
Eli Lilly presented positive Phase 3 pediatric ulcerative colitis data for mirikizumab, a first-in-class IL-23p19 inhibitor for children.
likely upward pressure as market prices in potential new pediatric indication.
First disclosure of efficacy results; pediatric UC market is currently underserved, creating upside potential.
Market effects
strengthens the IL‑23 inhibitor segment and may pressure competing pediatric UC therapies.
U.S. biotech investors likely to react; European and Asian markets may follow.
adds a new pediatric indication to a global drug pipeline, influencing worldwide biotech sentiment.
Counterpoint
If regulatory review is delayed or safety concerns emerge, the rally could be short‑lived.
Key entities
- CompanyEli Lilly and Company
Pharmaceutical developer of mirikizumab.
- DrugMirikizumab
IL‑23p19 inhibitor under investigation for pediatric UC.
- EventAmerican College of Gastroenterology (ACG) 2026
Venue where the trial results were presented.
